Mahesh Krishnan Sells 7,304 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Trading Down 1.6%

NASDAQ HALO opened at $77.01 on Thursday. Halozyme Therapeutics, Inc. has a 52 week low of $52.72 and a 52 week high of $82.22. The firm has a 50 day moving average of $68.96 and a two-hundred day moving average of $69.23. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The stock has a market capitalization of $9.13 billion, a PE ratio of 27.70, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.During the same quarter in the prior year, the business posted $1.11 EPS. The business’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Morgan Stanley reduced their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently modified their holdings of HALO. Western Wealth Management LLC purchased a new position in Halozyme Therapeutics in the 1st quarter valued at $229,000. Alpine Woods Capital Investors LLC purchased a new stake in shares of Halozyme Therapeutics in the first quarter valued at about $281,000. Glenmede Trust Co. NA boosted its holdings in shares of Halozyme Therapeutics by 22.4% in the first quarter. Glenmede Trust Co. NA now owns 146,717 shares of the biopharmaceutical company’s stock valued at $9,482,000 after acquiring an additional 26,851 shares in the last quarter. Argent Capital Management LLC increased its stake in shares of Halozyme Therapeutics by 52.2% during the first quarter. Argent Capital Management LLC now owns 9,054 shares of the biopharmaceutical company’s stock worth $585,000 after acquiring an additional 3,104 shares during the period. Finally, BankChampaign National Association acquired a new position in shares of Halozyme Therapeutics during the first quarter worth about $228,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.